Eazyplex Candida auris

Avoid ineffective therapy and hygiene management!

In healthcare across Europe, Candida auris continuously poses a risk to patients due to its propensity to cause outbreaks coupled with its resistance to antifungal drugs. A lack of awareness and difficulties in laboratory indentification of this Candida species can delay an early detection, which would reduce the potential increase for a horizontal transfer. 

C. auris was first identified in 2009, where within a few years of this identification has become the cause of numerous healthcare-related infections. Outbreaks have been reported in the countries of five different continents with the number of C. auris cases in European countries increasing significantly since the last ECDC rapid assessment of the risk of C. auris in Dec. 2016.

Remaining, is a need to raise awareness of C. auris in European healthcare settings to ensure that they can adapt their laboratory testing strategies and implement improved infection prevention, and control measures where appropriate.

European Center for Disease Prevention and Control. Candida auris in healthcare settings - Europe - first update, 23 April 2018. Stockholm: ECDC; 2018